Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142Phase 3Recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of azetukalner in generalized tonic-clonic seizure (GTCS), sponsored by Xenon Pharmaceuticals. Started Feb 2023; status: recruiting.
02
Drugs
azetukalner
03
Conditions
generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on NCT05667142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667142.